💊 The Big Next Step 📈 

By Imagine Biotech

👨‍⚕️New Hope for HNSCC Patients 😷 

GlycoMira Therapeutics has officially received IND approval for GM-1111 from the FDA, paving the way for clinical trials and marking a major milestone in the fight against HNSCC. This groundbreaking therapeutic has already shown incredible promise in preclinical studies—reducing mucositis, shrinking tumors, and protecting healthy tissue from radiation damage. With this FDA green light, GlycoMira is now set to take GM-1111 into human trials, bringing us one step closer to a transformative treatment for patients battling HNSCC. Imagine Biotech is proud to have played a support role in this journey, and we can't wait to see what's next! A press release from GlycoMira is below:

After joining the project, Imagine Biotech’s advanced technologies and rigorous testing protocols generated critical data that minimized risk for both patients and investors. This has played a key role in accelerating GlycoMira’s clinical development program for GM-1111 as the company progressed toward their IND application. Below is a testimonial from Dr. William Tew, PhD, CEO, and Chairman of GlycoMira.

🎯 Our Goal - Reaffirmed ✅ 

Our goal at Imagine Biotech is to de-risk investor capital to get high quality drugs to market as efficiently as possible, saving lives and helping individuals suffering from unbearable diseases.

The move towards Phase 1a Clinical Trials by GlycoMira that was made possible in part due to the scientific due diligence of Imagine Biotech reaffirms our goal. We are so incredibly proud to be a part of such a development and look to the future with hope for investors and patients alike.

The Imagine Biotech Solution 🔬 

Imagine Biotech resources can call upon a wide variety of technologies to de-risk your portfolio using sophisticated pathways that have matured due to improved data resources, confounding factors, and improved model assumptions.

Our array of services range from sophisticated molecular modeling density functional methods (DFT) to the first-of-its-kind integration package of ADMET and PK predictions to academic risk.

Imagine Biotech staff have the training, expertise, and knowledge to review the proposed hypotheses (investment) in their entire journey to commercialization and select those tests/technologies to support further investment success or flag issues that arise only in the environment of review by skilled biotechnology experts.

We believe that informed investments are the cornerstone of progress. Our mission is to empower investors with the insights and tools necessary to navigate the complexities of biotech investments with confidence.